Eculizumab for refractory thrombosis in antiphospholipid syndrome

Antiphospholipid syndrome (APS) is characterized by arterial and/or venous thrombosis with antiphospholipid antibodies. Dysregulation of the complement pathway has been implicated in APS pathophysiology. We report the successful use of eculizumab, an anti-C5 monoclonal antibody, in controlling and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussain, Habiba, Tarantino, Michael D., Chaturvedi, Shruti, McCrae, Keith R., Roberts, Jonathan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Exceptional Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864643/
https://www.ncbi.nlm.nih.gov/pubmed/35051999
http://dx.doi.org/10.1182/bloodadvances.2021005657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864643/
https://www.ncbi.nlm.nih.gov/pubmed/35051999
http://dx.doi.org/10.1182/bloodadvances.2021005657

Ejemplares similares